Jan 2014 update
Description
Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI), disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. The Company’s lead product candidate, EVK-001, is in late stage clinical testing. EVK-001 is a formulation of this drug, designed to provide systemic delivery of metoclopramide through intranasal administration. Gastroparesis is a condition of delayed gastric emptying in the absence of mechanical obstruction. Gastroparesis results in food remaining in the stomach for a longer time than normal, yielding a variety of symptoms.
Address
Suite 385, 12555 High Bluff Drive
SAN DIEGO, CA 92130
United States
SAN DIEGO, CA 92130
United States
Website
http://www.evokepharma.comKey stats and ratios
| Q2 (Jun '13) | 2012 | |
| Net profit margin | - | - |
| Operating margin | - | - |
| EBITD margin | - | - |
| Return on average assets | -55.40% | -395.07% |
| Return on average equity | - | - |
| Employees | 2 |
No comments:
Post a Comment